Renal cell carcinoma treatment

TopicLeading institutions, researchers & key papers

This cluster of papers represents a comprehensive exploration of advancements in the research and treatment of renal cell carcinoma, including studies on various treatment modalities, prognostic factors, molecular characterization, nephron-sparing surgery, immunotherapy, genetic mutations, and clinical guidelines.

415

Works

IDs:OpenAlex

How has Renal cell carcinoma treatment's publication output changed over time?

ScholarIQpublication output · 2001–2021

Output grew100% over the shown period — from 1 works in 2001 to 2 in 2021.

2001200220032007200920132015201820192021

What are the most-cited papers on Renal cell carcinoma treatment?

ScholarIQmost cited works

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Ray McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A.B. Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li-An Xu, Ian M. Waxman, Padmanee Sharma

New England Journal of Medicine. 20155,921 CitationsOPEN ACCESS

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier

New England Journal of Medicine. 20184,691 CitationsOPEN ACCESS

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Gary R. Hudes, Michael A. Carducci, Piotr Tomczak, Janice Dutcher, Robert A. Figlin, Anil Kapoor, Elżbieta Starosławska, Jeffrey A. Sosman, David McDermott, I. Bodrogi, Zoran Kovačević, Vladimir Lesovoy, Ingo G.H. Schmidt‐Wolf, О. Л. Барбараш, Erhan Gökmen, Timothy E. O’Toole, Stephanie Lustgarten, Laurence Moore, Robert J. Motzer

New England Journal of Medicine. 20073,653 Citations

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

James Chih‐Hsin Yang, Leah Haworth, Richard M. Sherry, Patrick Hwu, Douglas J. Schwartzentruber, Suzanne L. Topalian, Seth M. Steinberg, Helen X. Chen, Steven A. Rosenberg

New England Journal of Medicine. 20032,707 CitationsOPEN ACCESS

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen, Brian I. Rini, Laurence Albigès, Matthew T. Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Négrier, Motohide Uemura, Jae L. Lee, Aleksandr Vasiliev, Wilson H. Miller, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Jens Bedke, B. Yа. Alekseev, Jing Wang, Mariangela Mariani, Paul B. Robbins, Aleksander Chudnovsky, Camilla Fowst, Subramanian Hariharan, Bo Huang, Alessandra di Pietro, Toni K. Choueiri

New England Journal of Medicine. 20192,569 CitationsOPEN ACCESS